ERBB2 and breast carcinoma: Trastuzumab, on the other hand, resulted in a slight to moderate reduction in cell viability in four HER2 IHC2+ breast cancer cell lines compared to IHC 3 + BT474 and SKBR3 cells that were sensitive to trastuzumab (IC50 < 10 μg/ml) (Figure S1C).